Johnson & Johnson has seen a 28% year-to-date return in 2026, outperforming market benchmarks. Despite strong Q2 results and upgraded guidance driven by pharmaceutical growth, the stock is now trading at a premium valuation. Analysts recommend a "hold" rating due to potential MedTech softness, ongoing litigation, and macroeconomic uncertainties, despite its technical uptrend.
Pluang
Original source
pluang id
Check live status on DownRightNow
We wrap up our coverage of the markets and the week.
Bitcoin and Ether bears get decimated amid 'squeeze-led' rally and Musk's X wants to pay creators in stablecoins: Crypto's week in 5 stories CoinDesk Why bitcoin prices are suddenly rallying big-time Yahoo Finance Bitcoin jumps further on U.S. crypto policy hopes CP24 Bitcoin and gold surge as Bessent's bond market intervention weighs on dollar Financial Post Gold and Bitcoin Are Rallying as Debasement Chatter Picks Up Bloomberg.com
Last week, the BSE benchmark Sensex declined 276.32 points, or 0.35 per cent, and the NSE Nifty dipped 76.35 points, or 0.31 per cent
Banks, fintechs, NPCI: Who gets what when MDR returns to UPI Moneycontrol.com Keeping UPI accessible, secure and trusted: Balancing free payments with systemic growth Deccan Herald Selective UPI MDR Will Need Reliable Merchant Intelligence, Not Just a Pricing Rule TheWire.in Keep UPI free, and fund it from the savings it generates The Indian Express MDR on UPI transactions worth ₹2,000 & above likely in 2 weeks: Report | Zero MDR was introduced in January 2020 | Inshorts Inshorts
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer